{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-116468","form_type":"8-K","ticker":"TELA","cik":"0001561921","company_name":"TELA Bio, Inc.","filed_at":"2022-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.168060+00:00","generated_at":"2026-06-22T01:13:37.101560+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"TELA Bio Q3 revenue $11.2M (+46% YoY); reaffirms FY2022 guidance $42-45M","bullets":["Q3 revenue $11.2M, up 46% YoY; gross margin 66% vs 60% a year ago.","Net loss $10.7M vs $8.3M; operating loss $9.5M vs $7.2M in Q3 2021.","Reaffirmed FY2022 revenue guidance $42-45M (43-53% growth over FY2021).","OviTex revenue +29% YoY, OviTex PRS +108% YoY; BRAVO study shows 2.6% recurrence rate.","Closed August oversubscribed public offering netting $34.4M; cash $54.2M at quarter end."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-116468","json":"https://secwatch.observer/filing/0001104659-22-116468.json","markdown":"https://secwatch.observer/filing/0001104659-22-116468.md","text":"https://secwatch.observer/filing/0001104659-22-116468.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1561921/000110465922116468/0001104659-22-116468-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1561921/000110465922116468/tm2230071d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T01:13:37.101560+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d21e3567f83a3776c585c368b93f52059fe5992e","claim":"TELA Bio, Inc. reported the third quarter ended September 30, 2022 results: revenue $11.2 million, net income $10.7 million. Guidance reaffirmed.","evidence_excerpt":"and restoration of the patient's own anatomy, today reported financial results for the third quarter ended September 30, 2022. Recent Highlights · Reported revenue of $11.2 million for the third quarter, representing growth of 46% over the same quarter of 2021; · Increased demand for OviTex ® and OviTex PRS Reinforced Tissue Matrix products in the third","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1561921/000110465922116468/0001104659-22-116468-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2022"},{"label":"Revenue","value":"$11.2 million"},{"label":"Net income","value":"$10.7 million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}